<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Thrombosis Adviser News</title>
<link href="http://www.thrombosisadviser.com" ></link>
<id>urn:uuid:866be811-7e6f-2164-41a1-475d023dca6b</id>
<updated>2012-02-04T08:35:06+01:00</updated>
<author><name>Thrombosis Adviser News</name>
</author>
<subtitle>Latest Updates and News on ThrombosisAdviser.com</subtitle>
<entry>
<title>Rivaroxaban Tied to Lower Brain Bleed Risk in A&#45;Fib</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Rivaroxaban+Tied+to+Lower+Brain+Bleed+Risk+in+A-Fib#news1060" ></link>
<id>urn:uuid:de46749f-f318-f9af-925c-d649e30a53b2</id>
<updated>2012-02-03T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[A once daily oral dose of rivaroxaban significantly lowers the risk of intracranial hemorrhage in patients with atrial fibrillation at moderate to high risk of stroke, according to a study presented at the American Heart Association's International Stroke Conference, held from Feb. 1 to 3 in New Orleans.]]></summary>
</entry>
<entry>
<title>Apixaban more effective than aspirin in reducing stroke recurrence</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Apixaban+more+effective+than+aspirin+in+reducing+stroke+recurrence#news1059" ></link>
<id>urn:uuid:2b756453-9388-4970-d753-f0707dbd0921</id>
<updated>2012-02-03T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The oral factor Xa inhibitor apixaban was more effective than aspirin in reducing the risks for stroke and systemic embolism in patients with atrial fibrillation who have already experienced a stroke or transient ischemic attack and are unsuitable for warfarin therapy.]]></summary>
</entry>
<entry>
<title>Decision Support Tools Help Optimize Acute PE Detection</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Decision+Support+Tools+Help+Optimize+Acute+PE+Detection#news1058" ></link>
<id>urn:uuid:0ec94046-6ec2-53ab-5e81-50cd4690d39c</id>
<updated>2012-02-03T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Implementing evidence-based clinical decision support significantly improves the efficiency of computed tomographic angiography use to detect acute pulmonary embolism for patients presenting to an emergency department, according to a study published in the February issue of Radiology.]]></summary>
</entry>
<entry>
<title>ACE Inhibitors Not Linked to Improved Outcomes After ACS</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ACE+Inhibitors+Not+Linked+to+Improved+Outcomes+After+ACS#news1057" ></link>
<id>urn:uuid:d1d922fd-f8d2-2145-e998-7f65833b0cd3</id>
<updated>2012-02-03T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[For patients with acute coronary syndrome, prior chronic use of an angiotensin-converting enzyme inhibitor is not independently associated with improved in-hospital outcomes, according to a study published in the Feb. 1 issue of The American Journal of Cardiology.]]></summary>
</entry>
<entry>
<title>Rates of VTE after surgery vary by procedure type</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Rates+of+VTE+after+surgery+vary+by+procedure+type#news1056" ></link>
<id>urn:uuid:3aba7195-74c1-80ca-afb3-cb2951928732</id>
<updated>2012-01-23T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Using current venous thromboembolism preventive medications, approximately 1 in every 100 patients undergoing knee replacement and 1 in every 200 patients undergoing hip replacement will develop a VTE before hospital discharge, according to a review and analysis of previous studies.]]></summary>
</entry>
<entry>
<title>Warfarin Patients With Head Trauma Need Second CT Scan</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Warfarin+Patients+With+Head+Trauma+Need+Second+CT+Scan#news1055" ></link>
<id>urn:uuid:b324d48e-8049-6e5a-406a-d3b74adc71c7</id>
<updated>2012-01-23T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[For patients on warfarin with minor head trauma who have an initial negative computed tomography (CT) scan, 24-hour observation followed by an additional CT scan identifies the majority of cases of delayed bleeding, according to a study published online Jan. 16 in the Annals of Emergency Medicine.]]></summary>
</entry>
<entry>
<title>New AF ablation consensus doc previewed at Boston AF symposium</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=New+AF+ablation+consensus+doc+previewed+at+Boston+AF+symposium#news1054" ></link>
<id>urn:uuid:de10b29c-fc3a-b4b1-b952-a39f619e6832</id>
<updated>2012-01-11T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The forthcoming international consensus statement on atrial fibrillation (AF) includes a new set of standardized definitions, indications classed by evidence-level, and more information about anticoagulant therapy, among other improvements to the first AF ablation consensus released in 2007.]]></summary>
</entry>
<entry>
<title>Dabigatran Tied to Increase in Heart Attack Risk</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Dabigatran+Tied+to+Increase+in+Heart+Attack+Risk#news1053" ></link>
<id>urn:uuid:5bc44787-415c-354c-ed72-3c408e74ee8c</id>
<updated>2012-01-11T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The direct thrombin inhibitor dabigatran appears to raise the risk of myocardial infarction or acute coronary syndromes, according to a meta-analysis of seven randomized clinical trials published online Jan. 9 in the Archives of Internal Medicine. ]]></summary>
</entry>
<entry>
<title>Fondaparinux Reduces Events From Superficial Vein Thromboses</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Fondaparinux+Reduces+Events+From+Superficial+Vein+Thromboses#news1052" ></link>
<id>urn:uuid:1b273683-3971-dd82-a179-1710e2d65d57</id>
<updated>2012-01-11T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[In patients with spontaneous, isolated superficial vein thrombosis, a 45-day course of fondaparinux significantly reduced the rate of systemic thromboembolic complications compared with placebo, including events linked to thrombi with extensions more than 3 cm from the saphenofemoral junction, according to results of a post hoc analysis from the CALISTO trial.]]></summary>
</entry>
<entry>
<title>Risk for very late stent thrombosis&#44; late TLR rose steadily up to 5 years after stenting</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+for+very+late+stent+thrombosis%2C+late+TLR+rose+steadily+up+to+5+years+after+stenting#news1051" ></link>
<id>urn:uuid:7dffa6ca-4841-3cb7-38d0-2bedbb35cdb6</id>
<updated>2012-01-11T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[After implantation of sirolimus-eluting stents, the risk for very late stent thrombosis and late target lesion revascularization remained steady up to 5 years, according to study data from the j-Cypher Registry.]]></summary>
</entry>
<entry>
<title>Heparin Bridging Associated With Increased Bleeding Risk</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Heparin+Bridging+Associated+With+Increased+Bleeding+Risk#news1050" ></link>
<id>urn:uuid:083cac6f-b319-c3d5-1064-96b4be921129</id>
<updated>2012-01-06T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Patients who receive heparin bridging during an interruption of oral anticoagulation appear to be at a 5.4-fold increased risk of overall bleeding and a 3.6-fold increased risk of major bleeding, without a reduction in risk of thromboembolic events.]]></summary>
</entry>
<entry>
<title>Enoxaparin failed to reduce mortality in acutely ill patients </title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Enoxaparin+failed+to+reduce+mortality+in+acutely+ill+patients#news1049" ></link>
<id>urn:uuid:0bcbc45b-ce56-19c7-4cd8-e7342be6bc07</id>
<updated>2012-01-05T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The use of enoxaparin in addition to graduated compression stockings for thromboprophylaxis did not improve 30-day all-cause mortality among hospitalized, acutely ill patients, according to results from the LIFENOX trial.]]></summary>
</entry>
<entry>
<title>Rivaroxaban approved in Europe for AF and DVT treatment</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Rivaroxaban+approved+in+Europe+for+AF+and+DVT+treatment#news1048" ></link>
<id>urn:uuid:17b91889-5023-0dcd-f929-1045bcd2af78</id>
<updated>2011-12-20T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The factor Xa oral anticoagulant rivaroxaban (Xarelto, Bayer/Johnson & Johnson) has been approved in the European Union for the prevention of nonvalvular AF-related stroke and systemic embolism and for the treatment of deep venous thrombosis (DVT).]]></summary>
</entry>
<entry>
<title>Malaysia the first Asian country to use stroke medication</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Malaysia+the+first+Asian+country+to+use+stroke+medication#news1047" ></link>
<id>urn:uuid:db3ea108-a54e-a32f-5cd6-342e5b582780</id>
<updated>2011-12-19T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[KUALA LUMPUR: Malaysia has approved the use of rivaroxaban, a once-daily oral anticoagulant for reduction of stroke-risk in patients with sustained irregular heart rhythm.]]></summary>
</entry>
<entry>
<title>ASH&#58; Rivaroxaban Better in Practice than Expected</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ASH%3A+Rivaroxaban+Better+in+Practice+than+Expected#news1046" ></link>
<id>urn:uuid:ed65fdf4-cbee-0de5-a8ef-816939e41d9f</id>
<updated>2011-12-15T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The anticoagulant drug rivaroxaban (Xarelto) has turned out better in everyday clinical practice for preventing venous thromboembolism (VTE) in surgery patients than expected from the drug's registration studies, a German researcher said here.]]></summary>
</entry>
<entry>
<title>ASH&#58; Catheter&#45;Directed Thrombolysis Cuts DVT Risks</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ASH%3A+Catheter-Directed+Thrombolysis+Cuts+DVT+Risks#news1045" ></link>
<id>urn:uuid:012d6fae-9db8-4ad2-df23-a1af2bdd1db2</id>
<updated>2011-12-15T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[For patients with deep vein thrombosis, additional catheter-directed thrombolysis reduces the frequency of post-thrombotic syndrome and improves iliofemoral patency, according to a study published online Dec. 13 in The Lancet.]]></summary>
</entry>
<entry>
<title>Warfasa&#58; Aspirin associated with 40&#37; reduced risk for unprovoked VTE recurrence</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Warfasa%3A+Aspirin+associated+with+40%25+reduced+risk+for+unprovoked+VTE+recurrence#news1044" ></link>
<id>urn:uuid:7dd2fda4-27fc-2e7c-09bd-d7b553ae1513</id>
<updated>2011-12-15T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Aspirin, when administered 6 to 12 months after anticoagulant therapy, was associated with a significant reduced risk for recurrence of unprovoked venous thromboembolism, according to results from the Warfasa study.]]></summary>
</entry>
<entry>
<title>Blood clot risk halved for patients checking own warfarin dose</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Blood+clot+risk+halved+for+patients+checking+own+warfarin+dose#news1043" ></link>
<id>urn:uuid:d82da7bc-de61-8b2d-5b65-d302402134ee</id>
<updated>2011-12-02T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Patients who monitor their own treatment with warfarin or other blood-thinning drugs reduce their risk of developing blood clots by half, an Oxford University study has found. ]]></summary>
</entry>
<entry>
<title>NEJM&#58; Warfarin culprit for most hospitalizations in elderly&#59; management may help </title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=NEJM%3A+Warfarin+culprit+for+most+hospitalizations+in+elderly%3B+management+may+help#news1042" ></link>
<id>urn:uuid:bd853e4b-6830-183e-c1c8-9cdfbf8b2470</id>
<updated>2011-12-01T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Warfarin, the most commonly prescribed and trickiest to manage anticoagulant, is the key culprit of hospitalizations for the elderly patient population, according to a study published Nov. 24 in the New England Journal of Medicine. ]]></summary>
</entry>
<entry>
<title>Patients With Autoimmune Disorders Have Higher Risk Of Pulmonary Embolism</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Patients+With+Autoimmune+Disorders+Have+Higher+Risk+Of+Pulmonary+Embolism#news1041" ></link>
<id>urn:uuid:48e3661b-4dd4-c094-5f74-96ab9d15f47e</id>
<updated>2011-12-01T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[According to a report published Online First by The Lancet, individuals admitted to hospital for an autoimmune disorder have a significantly higher risk of experiencing a pulmonary embolism during the next 12 months.]]></summary>
</entry>
<entry>
<title>ELEVATE&#45;TIMI 52&#58; High&#45;dose clopidogrel reduced platelet reactivity in CYP2C19&#42;2 carriers</title>
<link href="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ELEVATE-TIMI+52%3A+High-dose+clopidogrel+reduced+platelet+reactivity+in+CYP2C19%2A2+carriers#news1040" ></link>
<id>urn:uuid:d5082efd-a80d-62e3-e221-f41ed2ffe6f7</id>
<updated>2011-11-16T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Higher doses of clopidogrel, up to 300 mg daily, were more effective than standard doses in patients with the CYP2C19 gene variant, according to late-breaking research from the ELEVATE-TIMI 56 trial. ]]></summary>
</entry>
</feed>
